87 patents
Page 2 of 5
Utility
Crispr/cas-mediated Gene Conversion
19 Jan 23
CRISPR/CAS-related compositions and methods for altering a cell or treating a disease, for example, by gene conversion, are disclosed.
Cecilia Cotta-Ramusino, Jennifer Leah Gori
Filed: 15 Feb 22
Utility
Crispr/cas-related Methods, Compositions and Components
5 Jan 23
CRISPR/Cas-related compositions and methods which provide for efficient gene editing of eukaryotic cells using modified gRNAs.
Gordon Grant Welstead, Jennifer Leah Gori, Jack Michael Heath, David A. Bumcrot
Filed: 10 Jan 22
Utility
CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS
8 Dec 22
Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.
Feng ZHANG, Deborah PALESTRANT, Beverly DAVIDSON, Jordi MATA-FINK, Edgardo RODRIGUEZ, Alexis BORISY
Filed: 14 Jun 22
Utility
Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
29 Nov 22
CRISPR/RNA-guided nuclease-related compositions and methods for treatment of A1AT deficiency and associated conditions are disclosed.
Shen Shen, Penrose O'Donnell, Minerva Sanchez
Filed: 24 Mar 17
Utility
Methods and systems for analyzing guide RNA molecules
15 Nov 22
The present disclosure relates to methods of assessing a sample of guide RNAs (gRNAs).
Cecilia Fernandez, Georgia Giannoukos, Luis Barrera, Dawn Ciulla, Terence Ta
Filed: 27 Apr 18
Utility
Evaluation of CAS9 Molecule/guide Rna Molecule Complexes
13 Oct 22
Disclosed herein are methods for evaluation, selection, optimization, and design of Cas9 molecule/gRNA molecule complexes.
Hariharan JAYARAM, William SELLECK
Filed: 22 Nov 21
Utility
Compositions and Methods for Treating CEP290-ASSOCIATED Disease
1 Sep 22
Compositions and methods for treatment of CEP290 related diseases are disclosed.
Morgan Lee MAEDER, Rina J. MEPANI, David A. BUMCROT, Shen SHEN, Michael STEFANIDAKIS
Filed: 11 Oct 21
Utility
CRISPR/cas-related methods and compositions for treating herpes simplex virus
19 Jul 22
Genome editing systems and genetic constructs that target a herpes simplex virus (HSV) viral gene, where the systems comprise one Cas9 molecule, and a gRNA molecule, compositions and cells comprising such genome editing systems and genetic constructs as well as methods for using the genome editing systems, genetic constructs, compositions and cells for genome engineering, and for preventing, treating or reducing HSV infection.
Ari E. Friedland, Penrose O'Donnell, David A. Bumcrot, Bryan R. Cullen
Filed: 26 Apr 19
Utility
Optimized CRISPR/cas9 systems and methods for gene editing in stem cells
19 Jul 22
The methods and compositions described herein surprisingly increase CRISPR/Cas-mediated gene editing in stem cells by transiently treating the cells with a stem cell viability enhancer prior to and/or after contacting the cells with one or more CRISPR/Cas9 components.
Jennifer Leah Gori
Filed: 6 May 16
Utility
CRISPR-related methods and compositions with governing gRNAS
19 Jul 22
Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.
Feng Zhang, Deborah Palestrant, Beverly Davidson, Jordi Mata-Fink, Edgardo Rodriguez, Alexis Borisy
Filed: 31 Mar 20
Utility
Cells Expressing a Recombinant Receptor from a Modified TGFBR2 Locus, Related Polynucleotides and Methods
16 Jun 22
Provided herein are engineered immune cells, e.g.
Stephen Michael Burleigh, Cedric CLEYRAT, Melissa CHIN, Fred HARBINSKI, Christopher Heath NYE, Blythe D. SATHER, Queenie VONG, G. GRANT WELSTEAD, Christopher WILSON
Filed: 30 Apr 20
Utility
CAS9 Fusion Molecules, Gene Editing Systems, and Methods of Use Thereof
16 Jun 22
Disclosed herein are enzymatically active Cas9 (eaCas9) fusion molecules, comprising an eaCas9 molecule linked, e.g., covalently or non-covalently, to a template nucleic acid; gene editing systems comprising the eaCas9 fusion molecules, and methods of use thereof.
Cecilia Cotta-Ramusino, Hariharan Jayaram, John Anthony Zuris
Filed: 20 Dec 21
Utility
Engineered CAS9 Nucleases
9 Jun 22
The present disclosure relates to Cas9 nuclease variants and methods of producing and using such variants.
Barrett Ethan Steinberg, Derek Cerchione
Filed: 14 Jul 21
Utility
Compositions and methods for treating CEP290-associated disease
24 May 22
Compositions and methods for treatment of CEP290 related diseases are disclosed.
Morgan Lee Maeder, Rina J. Mepani, David A. Bumcrot, Shen Shen, Michael Stefanidakis
Filed: 2 Aug 17
Utility
Modified Natural Killer (NK) Cells for Immunotherapy
12 May 22
The present disclosure is directed to the generation of NK cells (or other lymphocytes) from induced pluripotent cells that have been derived from cells, e.g., developmentally mature T cells, and uses thereof for immunotherapy.
Gordon Grant Welstead, Christopher Borges, Karrie Ka Wai Wong
Filed: 14 Feb 20
Utility
Crispr/cas-related Methods and Compositions for Treating Usher Syndrome and Retinitis Pigmentosa
5 May 22
CRISPR/Cas-related compositions and methods for treatment of Usher Syndrome and/or Retinitis Pigmentosa are disclosed herein.
Morgan L. MAEDER, David A. BUMCROT
Filed: 7 Jun 21
Utility
Crispr/rna-guided Nuclease-related Methods and Compositions for Treating Rho-associated Autosomal-dominant Retinitis Pigmentosa (Adrp)
5 May 22
CRISPR/RNA-guided nuclease-related compositions and methods for treatment of RHO-associated retinitis pigmentosa, e.g., autosomal-dominant retinitis pigmentosa (adRP).
Benjamin Aryeh DINER, Deepak REYON
Filed: 25 Feb 20
Utility
Compositions and Methods for Promoting Homology Directed Repair
10 Mar 22
This application provides improved methods of genome editing.
Cecilia Cotta-Ramusino
Filed: 4 Aug 21
Utility
Systems and Methods for the Treatment of Hemoglobinopathies
10 Mar 22
Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci in cells and increasing expression of fetal hemoglobin.
Jennifer Leah GORI, Edouard AUPEPIN DE LAMOTHE-DREUZY, Jack HEATH
Filed: 11 Sep 20
Utility
CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10)
8 Mar 22
CRISPR/CAS-related compositions and methods for treatment of Leber's Congenital Amaurosis 10 (LCA10) are disclosed.
Morgan Lee Maeder, David A. Bumcrot, Shen Shen
Filed: 19 Feb 19